证券日报网讯长春高新（000661）11月6日在互动平台回答投资者提问时表示，为持续提升公司核心竞 争力，公司聚焦内分泌代谢、女性健康等传统优势领域与肿瘤、呼吸、免疫相关创新方向，并稳步推进 有差异化和全球市场潜力的产品研发相关工作，目前有逾40种处于临床阶段或已提交新药临床试验申请 (IND)的候选药物。 ...

长春高新（000661.SZ）11月6日在投资者互动平台表示，为持续提升公司核心竞争力，公司聚焦内分泌 代谢、女性健康等传统优势领域与肿瘤、呼吸、免疫相关创新方向，并稳步推进有差异化和全球市场潜 力的产品研发相关工作，目前有逾40种处于临床阶段或已提交新药临床试验申请（IND）的候选药物。 （记者 张明双） 每经AI快讯，有投资者在投资者互动平台提问：公司的研发费用是三生制药的三倍以上，但是研发成 果不到其百分之一，请问这其中是否存在利益输送问题？公司没有研发能力为什么还要投入这么多资金 打水漂？ ...

长春高新在投资者互动平台回答称，为持续提升公司核心竞争力，公司聚焦内分泌代谢、女性健康等传 统优势领域与肿瘤、呼吸、免疫相关创新方向，并稳步推进有差异化和全球市场潜力的产品研发相关工 作，目前有逾40种处于临床阶段或已提交新药临床试验申请（IND）的候选药物。 ...

来源：格隆汇APP 轩竹生物是一家以创新为驱动的中国生物制药公司，凭借对中国医药行业的理解和对其独特临床需求的 洞察，改善患者健康和生活。自四环医药于2008年收购山东轩竹多数权益以来，公司已经建立一个全面 的内部研发平台，支持公司开发多样化且均衡的管线。自成立以来每年平均推进至少一款候选药物进入 临床试验，截至目前已获得共20项IND批准。 目前，轩竹生物有超过十种药物资产在积极开发中，涵盖消化系统疾病、肿瘤和非酒精性脂肪性肝炎 (NASH)，包括三项NDA批准资产，一个药物项目处于NDA注册阶段，一个药物项目处于III期临床试验 阶段，四个药物项目处于I期临床试验阶段，五个已获IND批准。(格隆汇) 格隆汇10月17日｜港股三大指数今日全线下跌，恒科指跌逾4%创逾一个月新低。由四环医药分拆的轩 竹生物-B(2575.HK)逆势走强，一度大涨17.1%至33.96港元，股价创上市新高。该股于本周三(15日)登陆 港交所，迄今仅仅3个交易日，现价较IPO价格11.6港元已累涨192.76%。 | | | 【 】HY199 4 (it : 51 TN 200 716 #K 19 29 39 109 150 30 ...

Group 1: China Biopharmaceutical (1177 HK) - The company announced a proposed acquisition of 95.09% of Lixin Pharmaceutical for a transaction price of up to $951 million, with a net payment of approximately $501 million after accounting for Lixin's estimated cash and bank deposits of $450 million on the closing date [1][2] - The acquisition will integrate Lixin's four differentiated technology platforms and eight clinical-stage drug candidates, including PD-1/VEGF bispecific antibody and GPRC5D ADC, which have licensing agreements with Merck and AstraZeneca totaling $4 billion [2] - The target price has been raised to HKD 8.00 based on the acquisition and cost reduction efforts, reflecting a potential upside of 17.3% [1][2] Group 2: Flat Glass (6865 HK) - The company expects a significant quarter-on-quarter increase in earnings for 1H25, with a projected profit of RMB 230-280 million, and a midpoint increase of 41% for 2Q25 [3] - The photovoltaic glass industry has seen substantial production cuts since June, with inventory accumulation slowing down, and prices are expected to bottom out and recover starting in August [3] - The target price has been slightly adjusted to HKD 11.45 due to the weaker-than-expected price trends, maintaining a buy rating [3] Group 3: Securities Industry - The securities industry is experiencing strong growth in earnings, with a projected year-on-year increase of 65%-80% for the first half of 2025, averaging a growth of 72% [6][7] - The brokerage business is expected to rebound significantly due to a low base from the previous year, with self-investment income being a major driver of profit growth [6] - The sector's valuation remains attractive, with the A-share securities industry index trading at a price-to-book ratio of 1.38, indicating potential for further valuation increases supported by strong earnings growth [6]